

Re: Your request made under the Freedom of Information Act 2000

Wilmington Healthcare is analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] – 10

- Adalimumab [Humira] – 143 for this drug but not this brand specifically
- Adalimumab Biosimilars

- Apremilast [Otezla] – 0
- Baricitinib [Olumiant] - 25
- Certolizumab [Cimzia] – 14

- Etanercept [Enbrel] - 11
- Etanercept Biosimilars

- Filgotinib [Jyseleca] - 12 but not this brand specifically

- Golimumab [Simponi] - 23
- Guselkumab [Tremfya] – **do not use**
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz] – 13
- Risankizumab [Skyrizi] – **do not use**
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara] - 3
- Secukinumab [Cosentyx] - 44
- Tocilizumab [Ro Actemra] - 23
- Tofacitinib [Xeljanz] - 2
- Upadacitinib [Rinvoq] - 4
- Ustekinumab [Stelara] - 0